Physician profile
Korin E Velez
NPI 1730582743
$776.99
in general payments reported to CMS, 2019-2025
15 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $190 · 2023: $104 · 2024: $342 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $206.64 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $117.27 | 2024-2025 | |
| Abbvie INC. | $97.94 | 2022-2025 | |
| Pfizer INC. | $92.94 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.65 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $30.07 | 2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $26.58 | 2022-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.46 | 2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.37 | 2024 | Caplyta |
| Dexcom, INC. | $18.19 | 2024 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $17.43 | 2024 | Daybue |
| Xeris Pharmaceuticals, INC. | $17.29 | 2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $16.27 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.06 | 2023 | Xifaxan |
| Exact Sciences Corporation | $13.83 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Korin Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.